|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2007-4-16
|
|
pubmed:abstractText |
Death receptor targeting is an attractive approach in experimental treatment for tumors such as malignant gliomas, which are resistant to radiation and chemotherapy. Among the family of cytokines referred to as death li gands, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has attracted clinical interest. The aim of this study was to assess whether TRAIL can be used as an adjuvant to temozolomide (TMZ) for apoptosis induction in malignant glioma cell lines.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0022-3085
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
106
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
646-51
|
|
pubmed:dateRevised |
2008-2-5
|
|
pubmed:meshHeading |
pubmed-meshheading:17432717-Antineoplastic Agents, Alkylating,
pubmed-meshheading:17432717-Apoptosis,
pubmed-meshheading:17432717-Cell Culture Techniques,
pubmed-meshheading:17432717-Cell Line, Tumor,
pubmed-meshheading:17432717-Cell Survival,
pubmed-meshheading:17432717-Dacarbazine,
pubmed-meshheading:17432717-Drug Therapy, Combination,
pubmed-meshheading:17432717-Glioma,
pubmed-meshheading:17432717-Humans,
pubmed-meshheading:17432717-TNF-Related Apoptosis-Inducing Ligand
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Enhanced proapoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand on temozolomide-resistant glioma cells.
|
|
pubmed:affiliation |
Department of Neurosurgery, Mount Sinai School of Medicine, New York, New York 10029, USA.
|
|
pubmed:publicationType |
Journal Article
|
